Latest Regulatory Clearance News

PointsBet has firmly dismissed Betr Entertainment’s unsolicited scrip takeover proposal, endorsing instead MIXI Australia’s superior all-cash offer. The board highlights significant risks and uncertainties tied to Betr’s bid while unanimously recommending shareholders accept MIXI’s $1.20 per share offer.

MAC Copper Limited has scheduled a key court hearing on July 30 to progress Harmony Gold’s recommended acquisition, moving closer to shareholder votes and regulatory approvals.

Insignia Financial has agreed to a $4.80 per share acquisition offer from CC Capital, representing a 56.9% premium over its recent share price. The Board unanimously recommends the scheme, pending regulatory and shareholder approvals.

Sky Network Television is set to acquire Discovery NZ for a nominal $1, instantly boosting its revenue by around NZD 95 million and expanding its digital footprint through the ThreeNow platform.

Brookfield has agreed to acquire ESR's remaining 19.9% stake in Cromwell Property Group, pending regulatory approval, signaling a major consolidation in the Australian real estate sector.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

TAL Dai-ichi Life Australia has obtained all necessary regulatory approvals, including from APRA, to finalize its minority investment in Challenger Limited, acquiring a 19.9% equity stake.

Dundee Precious Metals Inc. (DPM) has announced a recommended acquisition of Adriatic Metals Plc, valuing the company at approximately USD 1.322 billion. The deal offers Adriatic shareholders a mix of cash and shares, representing a significant premium and marking a major consolidation in the precious metals sector.

Dundee Precious Metals has published the detailed scheme document for its recommended acquisition of Adriatic Metals, setting the stage for shareholder votes in August 2025. The transaction, subject to regulatory approvals, aims to consolidate two key players in the precious metals mining sector.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.

Spacetalk Ltd has raised $3 million through convertible notes from its largest shareholder and converted $1 million of secured debt, positioning the company for international growth and new product development.

Ausgold Limited has raised A$35 million through a well-supported placement to accelerate its Katanning Gold Project in Western Australia towards a final investment decision.